Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Sanofi
Historische aandelenkoersen
Huidige aandelenkoers	€76.88
52 Week Hoogtepunt	€93.73
52 Week Laag	€71.73
Bèta	0.28
1 maand verandering	-4.83%
3 maanden verandering	-3.39%
1 Jaar Verandering	-16.56%
3 jaar verandering	-22.66%
5 jaar verandering	-12.60%
Verandering sinds IPO	84.81%

Recent nieuws en updates

Analyseartikel • May 04

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...

Recent updates

Analyseartikel • May 04

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...

Narratiefupdate • Apr 22

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution

Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.

Nieuw narratief • Apr 14

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?

Narratiefupdate • Apr 07

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion

Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.

Nieuw narratief • Mar 31

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?

Narratiefupdate • Mar 24

SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength

Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.

Narratiefupdate • Mar 09

SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience

Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.

Narratiefupdate • Feb 23

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability

Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.

Narratiefupdate • Feb 09

SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience

Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.

Narratiefupdate • Jan 25

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.

Narratiefupdate • Jan 11

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.

Narratiefupdate • Dec 25

SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline

Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.

Narratiefupdate • Dec 11

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.

Narratiefupdate • Nov 27

SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals

Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.

Narratiefupdate • Nov 10

SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution

Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.

Analyseartikel • Oct 31

We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative

Sanofi's ( EPA:SAN ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week...

Narratiefupdate • Oct 27

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Sanofi's analyst price target has been slightly lowered from €108.31 to €106.90. Analysts cite modest improvements in revenue growth and profit margin, but note a more conservative outlook for the company's future valuation.

Narratiefupdate • Sep 12

Pipeline Advances And Acquisitions Will Expand Therapeutic Horizons

Sanofi's slight decline in future P/E alongside an improved net profit margin suggests a modestly stronger earnings outlook, although this was not enough to materially shift the consensus analyst price target, which decreased fractionally from €109.22 to €108.31. What's in the News FDA approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) after insufficient response to previous treatment, based on positive Phase 3 results; also approved in UAE and under review in EU and China, with Fast Track and Orphan Drug designations for multiple indications.

Analyseartikel • Jul 27

Cautious Investors Not Rewarding Sanofi's (EPA:SAN) Performance Completely

With a median price-to-earnings (or "P/E") ratio of close to 16x in France, you could be forgiven for feeling...

Rendement voor aandeelhouders

	SAN	FR Pharmaceuticals	FR Markt
7D	3.9%	2.9%	2.0%
1Y	-16.6%	-10.6%	1.3%

Rendement versus industrie: SAN presteerde slechter dan de French Pharmaceuticals -sector, die het afgelopen jaar een rendement van -10.6 % opleverde.

Rendement versus markt: SAN presteerde slechter dan French Market, dat het afgelopen jaar een rendement van 1.3 % opleverde.

Prijsvolatiliteit

Is SAN's price volatile compared to industry and market?
SAN volatility
SAN Average Weekly Movement	3.0%
Pharmaceuticals Industry Average Movement	4.1%
Market Average Movement	5.4%
10% most volatile stocks in FR Market	10.7%
10% least volatile stocks in FR Market	2.9%

Stabiele aandelenkoers: SAN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de French markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van SAN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1994	74,846	Belen Garijo Lopez	www.sanofi.com

Sanofi, een bedrijf in de gezondheidszorg, houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van therapeutische oplossingen in de Verenigde Staten, Europa en internationaal. Het bedrijf levert immunologie en ontstekingen, zeldzame ziekten, neurologie, oncologie en andere geneesmiddelen en vaccins. Het biedt ook kindervaccins tegen poliomyelitis, pertussis en haemophilus influenzae type b (Hib); bescherming tegen respiratoir syncytieel virus en zeswaardige combinatievaccins tegen difterie, tetanus, pertussis, polio, Hib en hepatitis B; griep-, boost-, meningitis-, reis- en endemische vaccins, waaronder hepatitis A-, tyfus-, gele koorts- en rabiësvaccins.

Sanofi Samenvatting

Hoe verhouden de winst en inkomsten van Sanofi zich tot de beurswaarde?
SAN fundamentele statistieken
Marktkapitalisatie	€92.27b
Inkomsten(TTM)	€4.83b
Inkomsten(TTM)	€47.35b

19.1x

Koers/Winstverhouding

1.9x

P/S-verhouding

Is SAN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SAN resultatenrekening (TTM)
Inkomsten	€47.35b
Kosten van inkomsten	€13.09b
Brutowinst	€34.26b
Overige uitgaven	€29.44b
Inkomsten	€4.83b

Laatst gerapporteerde inkomsten

Mar 31, 2026

Volgende inkomensdatum

Jul 30, 2026

Winst per aandeel (EPS)	4.02
Brutomarge	72.36%
Nettowinstmarge	10.20%
Schuld/Eigen Vermogen Verhouding	24.9%

Hoe presteerde SAN op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

5.4%

Huidig dividendrendement

102%

Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/22 11:14
Aandelenkoers aan het einde van de dag	2026/05/22 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Sanofi wordt gevolgd door 53 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi (SAN) Aandelenoverzicht

Beloningen

Risicoanalyse

Analyst Price Targets

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Top Analyst Narratives

Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Sanofi Concurrenten

Ipsen

Virbac

Vetoquinol

Boiron

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Sanofi Demonstrates Superiority Of Efdoralprin Alfa Over Standard-Of-Care Augmentation Therapy In Achieving Higher Functional Alpha-1 Antitrypsin Levels In Alpha-1 Antitrypsin Deficiency

Sanofi Joins Global Study Advancing Blood Biomarkers for Alzheimer’s Detection and Diagnosis

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Sanofi Announces Board and Committee Changes

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Sanofi Demonstrates Superiority Of Efdoralprin Alfa Over Standard-Of-Care Augmentation Therapy In Achieving Higher Functional Alpha-1 Antitrypsin Levels In Alpha-1 Antitrypsin Deficiency

Sanofi Joins Global Study Advancing Blood Biomarkers for Alzheimer’s Detection and Diagnosis

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Sanofi Announces Board and Committee Changes

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of €4.12 per share

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience

Dividend increased to €4.12

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

New minor risk - Dividend sustainability

Full year 2025 earnings: EPS misses analyst expectations

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes